Opportunity Information: Apply for RFA AI 09 022
Apply for RFA AI 09 022
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "B Cell Immunology Partnership Program For HIV 1 Vaccine Discovery (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 16, 2009 and posted on Jun 16, 2009.
- Applicants must submit their applications by Dec 4, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities City or township governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts County governments Native American tribal governments (Federally recognized) Private institutions of higher education Special district governments State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The B Cell Immunology Partnership Program for HIV-1 Vaccine Discovery (U19) is a National Institute of Allergy and Infectious Diseases (NIAID), NIH funding opportunity designed to push forward early stage HIV-1 vaccine discovery by focusing on B cell biology and antibody responses. The central goal is to support multidisciplinary teams that can explain, in basic mechanistic terms, how to elicit broadly cross-reactive neutralizing antibodies (often referred to as broadly neutralizing antibodies, or bnAbs) in people who are not infected with HIV. In practical terms, the program is trying to answer a core vaccine problem: what immune pathways and vaccination approaches can reliably train the human immune system to produce antibodies capable of neutralizing many different HIV-1 strains, rather than just a narrow subset.
Scientifically, the FOA emphasizes two tightly linked research areas. First, it supports innovative work to identify and design new HIV-1 envelope (Env) immunogens, since Env is the main viral surface target for neutralizing antibodies. Applicants are expected to propose immunogen concepts and vaccination strategies aimed specifically at inducing broad and potent neutralization across diverse HIV-1 variants. Second, it supports foundational B cell immunology research that clarifies the immune mechanisms that enable or limit the development of these responses. This includes understanding how B cell responses are initiated, how they mature and are regulated, and what immunological bottlenecks prevent bnAb-like responses from arising after vaccination. The overall emphasis is not simply on testing many vaccine candidates, but on generating deep, generalizable knowledge about the rules governing protective antibody development and how those rules can be exploited by immunogen design and immunization regimens.
From a program structure standpoint, this is a U19 multi-project cooperative agreement. That means the award is intended to fund a coordinated set of interrelated projects under one umbrella, typically with multiple research components and shared cores, rather than a single independent research project. It is also a cooperative agreement rather than a standard grant, which generally signals substantial NIH programmatic involvement and an expectation of active collaboration, coordination, and shared milestones. A major feature of this FOA is the creation of a partnership network: U19 awardees are expected to communicate ideas and progress not only among themselves but also with investigators funded under an earlier, related initiative, B Cell Immunology for Protective HIV-1 Vaccines (U01; RFA-AI-07-014). The intent is to accelerate progress by aligning methods, sharing insights, and avoiding isolated efforts in a field where iterative learning and comparison across approaches is critical.
The FOA is explicitly non-clinical in scope in the sense that clinical trials are not supported. Applicants can propose substantial preclinical, translational, and mechanistic immunology work, but they should not structure the application around conducting human efficacy or clinical testing as trial activities under this award. Another key application expectation is that preliminary data are required, and applicants should clearly demonstrate expertise both in basic immunology and in HIV-1 virology. In other words, NIAID is looking for teams that already have credible traction in the science and can justify that their approaches are feasible and likely to yield meaningful mechanistic insight.
In terms of administrative details, the opportunity number is RFA-AI-09-022 and the activity is categorized under health research, with CFDA listings 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). It was posted June 16, 2009, with an original and current closing date of December 4, 2009, and it was archived January 4, 2010. The estimated total funding listed is $3,000,000, with an award ceiling of $1,000,000 (indicating the maximum anticipated amount per award, subject to NIH terms and the specific budget period structure). Cost sharing or matching is not required.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include small businesses; for-profit organizations (including those other than small businesses); nonprofit organizations with and without 501(c)(3) status; public and private institutions of higher education; federal agencies; state, county, city, township, special district, and certain school district governments; public or Indian housing authorities; federally recognized and other tribal governments and tribal organizations; and a variety of designated institution types such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities, and U.S. territories or possessions. Foreign organizations and regional organizations are also listed as eligible, which can matter for HIV research where scientific cohorts, viral diversity, and specialized expertise may be distributed globally.
Overall, this FOA is best understood as a coordinated, team-science mechanism meant to unlock the immunological logic of bnAb induction and translate that logic into better Env immunogens and immunization strategies, while ensuring that funded groups operate as an interactive partnership rather than as isolated laboratories. For the complete announcement and NIH-specific submission requirements and cooperative agreement expectations, the source link provided is http://grants.nih.gov/grants/guide/rfa_files/RFA-AI-09-022.html.
Frequently Asked Questions (FAQs)
What is the B Cell Immunology Partnership Program for HIV-1 Vaccine Discovery (U19)?
It is a National Institute of Allergy and Infectious Diseases (NIAID), NIH funding opportunity designed to advance early-stage HIV-1 vaccine discovery by focusing on B cell biology and antibody responses, with the goal of improving how vaccines could induce broadly protective neutralizing antibodies.
What is the central scientific goal of this funding opportunity?
The central goal is to support multidisciplinary teams that can explain, in basic mechanistic terms, how to elicit broadly cross-reactive neutralizing antibodies (broadly neutralizing antibodies, or bnAbs) in people who are not infected with HIV.
What core vaccine problem is the program trying to solve?
The program is targeting a key challenge in HIV vaccine development: identifying immune pathways and vaccination approaches that can reliably train the human immune system to produce antibodies that neutralize many different HIV-1 strains, rather than only a narrow subset.
What research areas does the FOA emphasize?
The FOA emphasizes two tightly linked areas: (1) identifying and designing new HIV-1 envelope (Env) immunogens and vaccination strategies aimed at broad and potent neutralization across diverse HIV-1 variants, and (2) foundational B cell immunology research to clarify mechanisms that enable or limit development of bnAb-like responses after vaccination.
Why is HIV-1 envelope (Env) a focus of this program?
Env is emphasized because it is the main viral surface target for neutralizing antibodies, and the program seeks innovative Env immunogen concepts intended to induce broad neutralization against diverse HIV-1 variants.
What kinds of outcomes is NIAID prioritizing in this program?
The emphasis is on generating deep, generalizable mechanistic knowledge about the rules governing protective antibody development and how those rules can be leveraged through immunogen design and immunization regimens, rather than simply testing many vaccine candidates.
What does it mean that this opportunity uses a U19 mechanism?
U19 is a multi-project cooperative agreement intended to fund a coordinated set of interrelated projects under one umbrella, typically involving multiple research components and shared cores, rather than a single independent research project.
What does it mean that this is a cooperative agreement rather than a standard grant?
A cooperative agreement generally indicates substantial NIH programmatic involvement and an expectation of active collaboration, coordination, and shared milestones among the funded teams and NIH.
Is collaboration across awardees expected?
Yes. A major feature is the creation of a partnership network. U19 awardees are expected to communicate ideas and progress among themselves and also with investigators funded under an earlier related initiative, B Cell Immunology for Protective HIV-1 Vaccines (U01; RFA-AI-07-014).
Why does the FOA emphasize a partnership network?
The intent is to accelerate progress by aligning methods, sharing insights, and avoiding isolated efforts in a field where iterative learning and comparison across approaches are considered critical.
Are clinical trials supported under this FOA?
No. The FOA is explicitly non-clinical in scope in the sense that clinical trials are not supported, and applications should not be structured around conducting human efficacy or clinical testing as trial activities under this award.
What types of research are allowed if clinical trials are not supported?
Applicants can propose substantial preclinical, translational, and mechanistic immunology work, as long as the application is not built around clinical trial activities.
Is preliminary data required for applications?
Yes. The FOA states that preliminary data are required.
What expertise is NIAID expecting applicant teams to demonstrate?
Applicants are expected to clearly demonstrate expertise in both basic immunology and HIV-1 virology, showing credible traction in the science and feasibility of the proposed approaches.
What is the opportunity number (FOA number) for this grant?
The opportunity number is RFA-AI-09-022.
What is the general category or area of this funding opportunity?
The activity is categorized under health research.
What CFDA numbers are associated with this opportunity?
The CFDA listings are 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research).
When was this funding opportunity posted and when did it close?
It was posted on June 16, 2009, and the original and current closing date is listed as December 4, 2009.
Is this FOA still active?
No. It was archived on January 4, 2010.
What is the estimated total funding and the award ceiling?
The estimated total funding listed is $3,000,000, and the award ceiling is $1,000,000 (the maximum anticipated amount per award, subject to NIH terms and the budget period structure).
Is cost sharing or matching required?
No. Cost sharing or matching is not required.
Who is eligible to apply?
Eligibility is broad and includes many domestic and non-domestic organization types, including small businesses; for-profit organizations; nonprofit organizations with and without 501(c)(3) status; public and private institutions of higher education; federal agencies; and many state and local government entities.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments, other tribal governments, and tribal organizations are listed as eligible.
Are U.S. territories or possessions included in the eligibility list?
Yes. U.S. territories or possessions are listed among eligible institution types.
Are foreign or non-U.S. organizations eligible to apply?
Yes. Foreign organizations and regional organizations are listed as eligible applicants.
Where can applicants find the complete announcement and official submission requirements?
The source link provided for the complete announcement is: http://grants.nih.gov/grants/guide/rfa_files/RFA-AI-09-022.html
Browse more opportunities from the same category: Health
Next opportunity: Floodplain Mapping and Floodplain Management Projects
Previous opportunity: Rehabilitation Training Rehabilitation Continuing Education Programs (RCEP) Institute on Rehabilitation Issues (IRI) CFDA 84.264C
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 09 022
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 09 022) also looked into and applied for these:
| Funding Opportunity |
|---|
| Community Prevention of Mother to Child Transmission (Community PMTCT) Apply for RFA 663 A 09 019 Funding Number: RFA 663 A 09 019 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $30,000,000 |
| Targeted Issues in Traumatic Brain Injury Juvenile Justice and TBI Apply for HRSA 09 261 Funding Number: HRSA 09 261 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Sickle Cell Treatment Demonstration Program Apply for HRSA 09 231 Funding Number: HRSA 09 231 Agency: Health Resources and Services Administration Category: Health Funding Amount: $390,000 |
| 2009 Eliminating Disparities in Lupus through Education and Training for Health Professionals (EDLET/HP) Apply for MP MPC 09 009 Funding Number: MP MPC 09 009 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $1,600,000 |
| Identification and Characterization of Sensitive Periods for Neurodevelopment in Studies of Mental Illness (R01) Apply for RFA MH 10 010 Funding Number: RFA MH 10 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Identification and Characterization of Sensitive Periods for Neurodevelopment in Studies of Mental Illness (R21) Apply for RFA MH 10 011 Funding Number: RFA MH 10 011 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| HIV Prevention in Zambian Communities Apply for 611 2009 05 RFI MODIFICATION 01 Funding Number: 611 2009 05 RFI MODIFICATION 01 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $2,500,000 |
| 2009 Curbing HIV/AIDS Transmission Among High Risk Minority Youth and Adolescents (CHAT) by Utilizing a Peer to Peer Outreach Model and New Application Technologies Apply for MP YEP 09 001 Funding Number: MP YEP 09 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| MCH Research Apply for HRSA 10 006 Funding Number: HRSA 10 006 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Core II Apply for CDC RFA CE09 906 Funding Number: CDC RFA CE09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Integration of ISO and Quality Management System Standards into National Public Health Laboratory Networks to Enhance Global Surveillance of Extremely Dangerous Pathogens Apply for CDC RFA CI09 905 Funding Number: CDC RFA CI09 905 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| 2009 HIV/AIDS Health Improvement for Re entering Ex Offenders Initiative (HIRE) Apply for MP HPP 09 001 Funding Number: MP HPP 09 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| Partnerships for Biodefense Viral Pathogens (R01) Apply for RFA AI 09 028 Funding Number: RFA AI 09 028 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Partnerships for Biodefense Food and Water borne Diseases (R01) Apply for RFA AI 09 027 Funding Number: RFA AI 09 027 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Enterics Research Investigational Network Cooperative Research Centers (U19) Apply for RFA AI 09 023 Funding Number: RFA AI 09 023 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Career Development Award to Promote Faculty Diversity/Re Entry in Biomedical Research (K01) Apply for RFA HL 10 012 Funding Number: RFA HL 10 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Minority Institutional Research Training Program (T32) Apply for RFA HL 10 014 Funding Number: RFA HL 10 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Career Award for Faculty at Minority Serving Institutions (K01) Apply for RFA HL 10 011 Funding Number: RFA HL 10 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Resource Core Alcohol Research Centers (P30) Apply for RFA AA 10 002 Funding Number: RFA AA 10 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Specialized Alcohol Research Centers (P50) Apply for RFA AA 10 003 Funding Number: RFA AA 10 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,800,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 09 022", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.